128 related articles for article (PubMed ID: 16369935)
1. Individualizing combination of two antiproliferative immunosuppressants with pharmacodynamic modeling of stimulated lymphocyte responses.
Berry V; Magill A; Yost M; Janosky J; Sindhi R
Cytometry A; 2006 Feb; 69(2):95-103. PubMed ID: 16369935
[TBL] [Abstract][Full Text] [Related]
2. Modeling individual variation in biomarker response to combination immunosuppression with stimulated lymphocyte responses-potential clinical implications.
Sindhi R; Allaert J; Gladding D; Haaland P; Koppelman B; Dunne J; Sehgal S
J Immunol Methods; 2003 Jan; 272(1-2):257-72. PubMed ID: 12505729
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic monitoring of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable kidney-allograft recipients.
Böhler T; Canivet C; Galvani S; Therville N; Salvayre R; Negre-Salvayre A; Durand D; Thomsen M; Rostaing L; Kamar N
Int Immunopharmacol; 2008 May; 8(5):769-73. PubMed ID: 18387521
[TBL] [Abstract][Full Text] [Related]
4. Assessment of immunosuppressive drug interactions: inhibition of lymphocyte function in peripheral human blood.
Barten MJ; Dhein S; Chang H; Bittner HB; Tarnok A; Rahmel A; Mohr FW; Gummert JF
J Immunol Methods; 2003 Dec; 283(1-2):99-114. PubMed ID: 14659903
[TBL] [Abstract][Full Text] [Related]
5. Cytokines and cell surface receptors as target end points of immunosuppression with cyclosporine A.
Sindhi R; Allaert J; Gladding D; Koppelman B; Dunne JF
J Interferon Cytokine Res; 2001 Jul; 21(7):507-14. PubMed ID: 11506745
[TBL] [Abstract][Full Text] [Related]
6. Antiproliferative profile of sirolimus and mycophenolate mofetil: impact of the SI/MPL ratio.
Voisard R; Geçgüner L; Baur R; Herter T; Hombach V
Int J Cardiol; 2005 Jul; 102(3):435-42. PubMed ID: 16004888
[TBL] [Abstract][Full Text] [Related]
7. Effect of mycophenolate mofetil therapy on lymphocyte activation in heart transplant recipients.
Weigel G; Griesmacher A; Karimi A; Zuckermann AO; Grimm M; Mueller MM
J Heart Lung Transplant; 2002 Oct; 21(10):1074-9. PubMed ID: 12398872
[TBL] [Abstract][Full Text] [Related]
8. The effect of sirolimus- or cyclosporine-based immunosuppression effects on T-cell subsets in vivo.
Libetta C; Sepe V; Zucchi M; Portalupi V; Meloni F; Rampino T; Dal Canton A
Kidney Int; 2007 Jul; 72(1):114-20. PubMed ID: 17410097
[TBL] [Abstract][Full Text] [Related]
9. Differential Effects of Tacrolimus versus Sirolimus on the Proliferation, Activation and Differentiation of Human B Cells.
Traitanon O; Mathew JM; La Monica G; Xu L; Mas V; Gallon L
PLoS One; 2015; 10(6):e0129658. PubMed ID: 26087255
[TBL] [Abstract][Full Text] [Related]
10. CD69 expression on peripheral CD4+ T cells parallels disease activity and is reduced by mycophenolate mofetil therapy in uveitis.
Kilmartin DJ; Fletcher ZJ; Almeida JA; Liversidge J; Forrester JV; Dick AD
Invest Ophthalmol Vis Sci; 2001 May; 42(6):1285-92. PubMed ID: 11328741
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood.
Barten MJ; Streit F; Boeger M; Dhein S; Tarnok A; Shipkova M; Armstrong VW; Mohr FW; Oellerich M; Gummert JF
Transplantation; 2004 Apr; 77(8):1154-62. PubMed ID: 15114077
[TBL] [Abstract][Full Text] [Related]
12. Sustained suppression of peripheral blood immune functions by treatment with mycophenolate mofetil correlates with reduced severity of cardiac allograft rejection.
Klupp J; van Gelder T; Dambrin C; Regieli JJ; Boeke K; Billingham ME; Morris RE
J Heart Lung Transplant; 2004 Mar; 23(3):334-51. PubMed ID: 15019644
[TBL] [Abstract][Full Text] [Related]
13. [Proliferation effects of sirolimus, cyclosporine A and mycophenolate mofetil on human transitional cell carcinoma cells].
Lin J; Wang YH; Zhang YH; Tian Y
Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(6):388-91. PubMed ID: 22490898
[TBL] [Abstract][Full Text] [Related]
14. Assay validation of phosphorylated S6 ribosomal protein for a pharmacodynamic monitoring of mTOR-inhibitors in peripheral human blood.
Dieterlen MT; Bittner HB; Klein S; von Salisch S; Mittag A; Tárnok A; Dhein S; Mohr FW; Barten MJ
Cytometry B Clin Cytom; 2012 May; 82(3):151-7. PubMed ID: 22213594
[TBL] [Abstract][Full Text] [Related]
15. Conversion to combined therapy with sirolimus and mycophenolate mofetil improved renal function in stable renal transplant recipients.
Tsai MK; Lee CY; Hu RH; Lee PH
J Formos Med Assoc; 2007 May; 106(5):372-9. PubMed ID: 17561472
[TBL] [Abstract][Full Text] [Related]
16. Novel assays of multiple lymphocyte functions in whole blood measure: new mechanisms of action of mycophenolate mofetil in vivo.
Barten MJ; van Gelder T; Gummert JF; Shorthouse R; Morris RE
Transpl Immunol; 2002 Jun; 10(1):1-14. PubMed ID: 12182459
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus and mycophenolate mofetil after liver transplantation.
Kniepeiss D; Iberer F; Grasser B; Schaffellner S; Tscheliessnigg KH
Transpl Int; 2003 Jul; 16(7):504-9. PubMed ID: 12687325
[TBL] [Abstract][Full Text] [Related]
18. Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model.
Eggenhofer E; Renner P; Soeder Y; Popp FC; Hoogduijn MJ; Geissler EK; Schlitt HJ; Dahlke MH
Transpl Immunol; 2011 Sep; 25(2-3):141-7. PubMed ID: 21704160
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine.
El Haggan W; Ficheux M; Debruyne D; Rognant N; Lobbedez T; Allard C; Coquerel A; Ryckelynck JP; Hurault de Ligny B
Transplant Proc; 2005 Mar; 37(2):864-6. PubMed ID: 15848558
[TBL] [Abstract][Full Text] [Related]
20. Kinetics of in vitro immune responses of T and B cells during tolerance induction by sirolimus.
Ghobrial R; Karczewski M; Ferraresso M; Tian L; Stepkowski SM; Kahan BD
Ann Transplant; 1996; 1(4):22-9. PubMed ID: 9869901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
